CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Berlin, Germany and 73 other locations
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...
Phase 3
Berlin, Germany and 64 other locations
study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...
Phase 3
Berlin, Germany and 40 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Potsdam, Germany and 122 other locations
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
Phase 3
Berlin, Germany and 312 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...
Phase 3
Potsdam, Germany and 301 other locations
Clinical trials
Research sites
Resources
Legal